ICSI indicates intracytoplasmic sperm injection; IVF, in vitro fertilization.
ART indicates assisted reproductive technology; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization.
Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in Use of and Reproductive Outcomes Associated With Intracytoplasmic Sperm Injection. JAMA. 2015;313(3):255-263. doi:10.1001/jama.2014.17985
Intracytoplasmic sperm injection (ICSI) is increasingly used in patients without severe male factor infertility without clear evidence of a benefit over conventional in vitro fertilization (IVF).
To assess national trends and reproductive outcomes for fresh IVF cycles (embryos transferred without being frozen) following the use of ICSI compared with conventional IVF with respect to clinical indications for ICSI use.
Design, Setting, and Population
Retrospective cohort study using data on fresh IVF and ICSI cycles reported to the US National Assisted Reproductive Technology Surveillance System during 1996-2012.
Main Outcomes and Measures
Trends in ICSI use during 1996-2012 with respect to male factor infertility, unexplained infertility, maternal age 38 years or older, low oocyte yield, and 2 or more prior assisted reproductive technology cycles; reproductive outcomes for conventional IVF and ICSI cycles during 2008-2012, stratified by the presence or absence of male factor infertility.
Of the 1 395 634 fresh IVF cycles from 1996 through 2012, 908 767 (65.1%) used ICSI and 499 135 (35.8%) reported male factor infertility. Among cycles with male factor infertility, ICSI use increased from 76.3% (10 876/14 259) to 93.3% (32 191/34 506) (P < .001) during 1996-2012; for those without male factor infertility, ICSI use increased from 15.4% (4197/27 191) to 66.9% (42 321/63 250) (P < .001). During 2008-2012, male factor infertility was reported for 35.7% (176 911/494 907) of fresh cycles. Among those cycles, ICSI use was associated with a lower multiple birth rate compared with conventional IVF (30.9% vs 34.2%; adjusted relative risk [RR], 0.87; 95% CI, 0.83-0.91). Among cycles without male factor infertility (n = 317 996), ICSI use was associated with lower rates of implantation (23.0% vs 25.2%; adjusted RR, 0.93; 95% CI, 0.91-0.95), live birth (36.5% vs 39.2%; adjusted RR, 0.95; 95% CI, 0.93-0.97), and multiple live birth (30.1% vs 31.0%; adjusted RR, 0.93; 95% CI, 0.91-0.95) vs conventional IVF.
Conclusions and Relevance
Among fresh IVF cycles in the United States, ICSI use increased from 36.4% in 1996 to 76.2% in 2012, with the largest relative increase among cycles without male factor infertility. Compared with conventional IVF, ICSI use was not associated with improved postfertilization reproductive outcomes, irrespective of male factor infertility diagnosis.
The introduction of intracytoplasmic sperm injection (ICSI) in 1992 revolutionized the treatment of couples with male factor infertility and made paternity possible for a large proportion of men with nonobstructive azoospermia, or no measurable sperm count.1,2 Over the past 2 decades, the use of ICSI for patients with borderline or even normal semen characteristics has increased,3 without clear evidence of a benefit to using ICSI over conventional in vitro fertilization (IVF).4- 6 The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology concluded that there is insufficient evidence to support the routine use of ICSI in patients without male factor infertility.7 Although ICSI may have a role in IVF cycles using preimplantation genetic testing, in vitro maturation, or previously cryopreserved oocytes, the routine use of ICSI for these indications requires further investigation.7
In contrast to conventional IVF, ICSI bypasses natural barriers to fertilization, thereby increasing the possibility of the transmission of genetic defects from one generation to the next. Pregnancies resulting from the use of ICSI have been associated with 1.5 to 4 times increased incidences of chromosomal abnormalities,8,9 imprinting disorders,10 autism,11 intellectual disabilities,11 and birth defects12,13 compared with pregnancies resulting from conventional IVF. These increased risks may be related to the effects of underlying male or female subfertility, other medical factors present in couples who are candidates for ICSI, or the ICSI procedure.
Intracytoplasmic sperm injection is also considerably more expensive than conventional IVF and adds to financial burdens already experienced by many couples undergoing fertility treatment.14,15 The higher reimbursement associated with ICSI has been postulated as one possible reason for the increasing use of this technology.
The aim of this study was to assess national trends and reproductive outcomes of fresh IVF cycles associated with the use of ICSI compared with conventional IVF with respect to clinical indications for ICSI use.
All data used in this study were derived from the National Assisted Reproductive Technology Surveillance System (NASS), a data reporting system for the federally mandated collection of information on all assisted reproductive technology (ART) cycles performed in the United States.16 In NASS, ART cycles are defined as fertility treatments in which eggs and sperm or embryos are handled (manipulated) for the purpose of establishing a pregnancy. NASS includes cycle-level information on patient characteristics, clinical characteristics of the ART procedure, and pregnancy outcomes. Multiple cycles among individual patients are not linked. NASS captures information from an estimated 97% of ART cycles performed annually.17 Each year, 7% to 10% of reporting clinics are randomly selected for validation and their reported data are compared with medical records. Discrepancy rates are calculated and are less than 5% with the exception of the following infertility diagnoses: diminished ovarian reserve (8.4%), other factor (9.5%), and unknown factor (6.5%).17
Because information on ICSI use is not consistently collected across clinics for frozen embryo cycles or cycles canceled prior to oocyte retrieval (ovarian stimulation or monitoring was initiated but cycle did not proceed to oocyte retrieval), we restricted our analysis to all fresh (embryos transferred without being frozen) conventional IVF and ICSI cycles performed from 1996 through 2012 in which oocyte retrieval was attempted. We used linear regression models to assess trends in the use of ICSI for all fresh cycles and for those with the following indications: male factor infertility (infertility due to abnormal semen characteristics, abnormal sperm function, or surgical sterilization), unexplained infertility (infertility with unidentified etiology), female patient aged 38 years or older, 2 or more prior ART cycles and no prior live birth, low oocyte yield (<5 oocytes retrieved), and use of preimplantation genetic testing. Annual ICSI rate was the dependent variable and year was the continuous predictor. Data collection for preimplantation genetic testing was implemented in 2004; thus, we evaluated this factor only for 2004 through 2012.
To account for advances in ICSI techniques and technology, we subsequently restricted the analysis to the 5 most recent years (2008-2012) and evaluated the association between ICSI and reproductive outcomes. We compared the distribution of patient and clinical characteristics between cycles using conventional IVF and ICSI, stratified by male factor and non–male factor infertility. The characteristics assessed in this study included female patient age, race/ethnicity (as reported by clinics), infertility diagnosis, number of prior live births, number of prior spontaneous abortions, number of prior ART cycles (includes prior fresh and frozen cycles), use of donor egg or embryo, use of donor sperm (including cycles using only donor sperm or mixed patient and donor sperm), number of oocytes retrieved, number of embryos transferred, embryo stage at transfer, number of embryos cryopreserved, use of assisted hatching (the purposeful disruption of an embryo’s zona pellucida by laser, mechanical, or chemical means), and use of genetic testing. Race/ethnicity was assessed for reported variations in IVF birth outcomes. NASS does not collect information on fertilization rates; therefore, we indirectly assessed rates of failed fertilization by calculating the percentage of cycles cancelled between retrieval and transfer for cycles using conventional IVF or ICSI, stratified by male factor and non–male factor infertility. We also compared rates of implantation, clinical intrauterine pregnancy, live birth, miscarriage, multiple live birth, preterm delivery (<37 weeks’ gestation), and low birth weight (<2500 g) for each strata.
To account for potential confounding by factors associated with ICSI use, we estimated propensity scores using logistic regression models with ICSI as the outcome and included all baseline covariates that may predict probability of treatment selection (age, infertility diagnosis, number of prior live births, number of prior spontaneous abortions, number of prior ART cycles, use of donor egg or embryo, use of donor sperm, and number of oocytes retrieved). Backward selection with a significance level of P<.05 was used to determine the final models. Separate propensity score models were estimated for cycles with and without male infertility. Because covariate adjustment using propensity scores produces unbiased estimates of rate ratios, we included the estimated propensity scores in all outcome models.18 We used robust Poisson regression models with generalized estimating equations for clustering by clinic to estimate unadjusted and adjusted risk ratios for the association between the use of ICSI and reproductive outcomes. The multivariable models included the aforementioned patient and clinical characteristics except race/ethnicity because of a high percentage (39.7%) of missing information. The models for cycle cancellation did not include assisted hatching, number of embryos transferred, and embryo stage at transfer because this information is not available for canceled cycles. Data were missing for less than 2% of all other covariates.
We also compared reproductive outcomes for conventional IVF and ICSI for subgroups with selected indications including unexplained infertility, age 38 years or older, 2 or more prior ART cycles and no prior live birth, low oocyte yield, and use of genetic testing. All models included propensity scores derived from indication-specific logistic regression models using backward selection with a significance level of P<.05.
For bivariable comparisons, we used Pearson χ2 tests and applied the Bonferroni method to control the familywise error rate due to multiple comparisons. We considered each stratum a “family” and multiplied the P values by 20. For the multivariate models, we also used the Bonferroni method to adjust the P values for the 8 outcomes assessed within each indication. A 2-tailed P<.05 was considered statistically significant. SAS version 9.3 was used for all analyses. The study was approved by the Centers for Disease Control and Prevention’s institutional review board. A waiver of informed consent was obtained.
NASS captured data on a total of 1 395 634 fresh IVF cycles from 1996 through 2012. Of these, 908 767 cycles (65.1%) used ICSI and 486 867 cycles (34.9%) used conventional IVF. Male factor infertility was reported for 499 135 cycles (35.8%) while no male factor diagnosis was reported for 896 499 cycles (64.2%). Overall, ICSI was used in 90.0% of cycles with male factor infertility and in 51.2% of cycles without male factor infertility.
The proportion of fresh IVF cycles using ICSI increased from 36.4% (15 073/41 450) in 1996 to 76.2% (74 512/97 756) in 2012 (Figure 1). Among cycles with a diagnosis of male factor infertility, ICSI use increased from 76.3% (10 876/14 259) to 93.3% (32 191/34 506) (P<.001). Among cycles with non–male factor infertility, ICSI use increased from 15.4% (4197/27 191) to 66.9% (42 321/63 250) (P<.001) during the study period.
During 1996 through 2012, ICSI use increased significantly for all selected non–male factor indications, as well as for cycles without any indication (Figure 2). From 2004 onward, when data on preimplantation genetic testing was available, the use of ICSI was highest when preimplantation genetic testing was used.
During 2008-2012, there were 494 907 fresh IVF cycles, 74.6% of which used ICSI (Table 1). Male factor infertility was identified in 35.7% of the cycles. Intracytoplasmic sperm injection was used in 92.9% of cycles with male factor infertility and in 64.5% of cycles without male factor infertility.
Among couples with male factor infertility, the female partners among those undergoing ICSI were younger, were less likely to have concomitant female factor infertility diagnoses, and had fewer prior live births and more prior ART cycles compared with those undergoing conventional IVF (Table 1). Cycles using ICSI had a larger number of oocytes retrieved, more day 5 transfers, more embryos cryopreserved, and higher rates of assisted hatching than those using conventional IVF. The proportion of cycles using donor sperm was much lower for ICSI compared with conventional IVF (4.2% vs 16.6%).
Among couples with non–male factor infertility, the female partners of those undergoing ICSI were more likely to be older than 40 years, to have diminished ovarian reserve, to have undergone 1 or more prior ART cycles, and to be nulliparous compared with those undergoing conventional IVF (Table 1). Use of donor oocytes, day 5 embryo transfer, use of assisted hatching, and use of preimplantation genetic testing was higher among cycles with ICSI than with conventional IVF.
Table 2 shows reproductive outcomes following conventional IVF and ICSI, stratified by the presence or absence of male factor infertility and adjusted for maternal factors and ART treatment characteristics. We tested models with and without the inclusion of a race/ethnicity covariate and found that the magnitude and direction of association did not change significantly when the variable was included. Among couples with male factor infertility, the percentage of cycles canceled between oocyte retrieval and embryo transfer was lower for cycles using ICSI than for those using conventional IVF (6.3% vs 13.6%; adjusted relative risk [RR], 0.50; 95% CI, 0.45-0.56). However, there were no differences in pregnancy, miscarriage, or live birth rates for transfers using ICSI compared with conventional IVF. The adjusted relative risks for implantation (25.5% vs 25.6%; adjusted RR, 0.95; 95% CI, 0.91-0.98) and multiple live birth (30.9% vs 34.2%; adjusted RR, 0.87; 95% CI, 0.83-0.91) were significantly lower in those undergoing ICSI compared with conventional IVF.
Among couples without male factor infertility, adjusted RRs for implantation (23.0% vs 25.2%; adjusted RR, 0.93; 95% CI, 0.91-0.95), pregnancy (44.9% vs 47.9%; adjusted RR, 0.95; 95% CI, 0.93-0.97), and live birth (36.5% vs 39.2%; adjusted RR, 0.95; 95% CI, 0.93-0.97) were significantly lower among cycles using ICSI compared with conventional IVF. The adjusted RRs for multiple birth (30.1% vs 31.0%; adjusted RR, 0.93; 95% CI, 0.91-0.95) and low birth weight (28.4% vs 28.5%; adjusted RR, 0.96; 95% CI, 0.94-0.99) were also lower in those undergoing ICSI compared with conventional IVF (Table 2).
When reproductive outcomes were examined among selected non–male factor indications for ICSI, the direction and magnitude of the adjusted RRs for the association between ICSI and conventional IVF followed patterns similar to those for the non–male factor infertility group as a whole (Table 3). Overall, cycles using ICSI tended to have lower cancellation, implantation, pregnancy, live birth, and multiple birth rates compared with cycles using conventional IVF, irrespective of the underlying indication.
The results of this analysis demonstrate a steady increase in the proportion of ART cycles involving ICSI performed in the United States from 1996 through 2012. The use of ICSI doubled during the study period, from 36.4% to 76.2% of all fresh IVF cycles, with the greatest increase occurring in cycles without male factor infertility. When male factor infertility was present, reproductive outcomes—including pregnancy, miscarriage, and live birth rates—were comparable for cycles that used ICSI vs conventional IVF after adjustment for maternal factors. Notably, the likelihood of cycle cancellation between retrieval and transfer, a surrogate measure of failed fertilization, was markedly decreased for cycles where ICSI was used compared with those using conventional IVF, thereby confirming that ICSI increases the likelihood of fertilization in the context of male factor infertility. In contrast, implantation rates were also lower when ICSI was used and likely contributed to the significantly lower rates of multiple live births. In the absence of male factor infertility, ICSI use was associated with small but statistically significant decreases in implantation, pregnancy, live birth, multiple live birth, and low birth weight rates compared with conventional IVF. Although such differences may be a function of the large sample size and thus not clinically relevant, our findings suggest that use of ICSI may improve fertilization rates but not implantation or pregnancy rates in the setting of unexplained infertility, advanced maternal age, and low oocyte yield.
The findings of this study are consistent with results of a previous study showing an increase in the use of ICSI from 1995 through 2004 despite stable rates of male factor infertility diagnosis.3 The increasing trend in ICSI use in the United States parallels the trend seen globally, although the relative frequency with which ICSI is used varies markedly among countries.19
We found that ICSI use increased in the absence of any indication, thereby suggesting that the decision to perform ICSI instead of conventional IVF was likely being influenced by other unmeasured factors. The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology statement that the use of ICSI for unexplained infertility, low oocyte yield, and advanced maternal age did not improve clinical outcomes was released only recently, in 20127; it remains to be seen how this statement might affect the use of ICSI for non–male factor indications in the future.
Our results demonstrated no improvement in postfertilization reproductive outcomes with use of ICSI over conventional IVF in the absence of male factor infertility, regardless of the underlying indication for use. On the contrary, reproductive outcomes were slightly poorer when ICSI was used in non–male factor cases. We found that use of ICSI was associated with lower rates of multiple birth regardless of whether male factor infertility was present; however, this finding may be due to lower implantation rates in cycles where ICSI was used. Our findings were consistent with those of a previous randomized clinical trial, which found only marginal increases in implantation and pregnancy rates in couples undergoing conventional IVF compared with ICSI in the absence of male factor infertility, leading the authors to conclude that ICSI offered no clinical advantage over conventional IVF in cases of non–male factor infertility.6
Statistically significant findings reported in the current study might have reflected the large sample size and might lack clinical relevance. It has been suggested that relative risks of 0.5 or less in observational studies warrant further investigation while those between 0.5 and 1 are likely due to selection bias and residual confounding.20 Alternatively, by bypassing natural selection, ICSI use could have resulted in poorer-quality embryos compared with conventional IVF, leading to poorer reproductive outcomes. Another possibility is that ICSI use was warranted in some of the non–male factor cases for reasons that were not captured by this study—for example, poor sperm or egg quality—which could have led to poorer reproductive outcomes. Last, ICSI could be used as a rescue measure for fertilizing oocytes that have failed to be fertilized with conventional IVF.21 Because primary failure of fertilization might be secondary to poor oocyte quality, the use of ICSI in this clinical setting could lead to an association with poorer reproductive outcomes.
The primary limitation of this study was that NASS does not collect information on fertilization rates, for which ICSI is expected to be advantageous compared with conventional IVF. Although we were able to indirectly assess fertilization failure using the number of cycles canceled following oocyte retrieval, this measure assumes that cycles not proceeding to embryo transfer represent those in which all oocytes failed to fertilize, which may not necessarily be true. Second, although it has been suggested that ICSI might be beneficial compared with conventional IVF for cryopreserved oocytes, NASS does not collect this information. Third, there is no direct measure of embryo quality in NASS data, which could have modified the reproductive outcomes of interest. Furthermore, we lacked details on male factor evaluation. Although the diagnosis of male factor infertility typically includes men with fewer than 500 000 total motile sperm present in the ejaculate or less than 4% of normal morphologic forms based on strict criteria, it is unknown whether all centers uniformly adhere to this definition. In addition, NASS data are cycle based, and we were unable to link cycles for patients undergoing more than 1 cycle. We also restricted the analysis to fresh cycles; however, it is unlikely that findings for frozen-thawed embryos would differ from those for fresh cycles since ICSI rates would be similar. Finally, our observational, retrospective cohort study may be subject to bias because of uncontrolled confounding.
An important strength of this study is the use of NASS, a large, comprehensive, national-level database with a sufficient sample size to allow for subgroup analyses. To our knowledge, trends in the use of ICSI in the context of the indications for ICSI and outcomes following its use have not been previously investigated or reported.
Among fresh-embryo IVF cycles in the United States, the use of ICSI increased from 36.4% in 1996 to 76.2% in 2012, with the largest relative increase noted among cycles without a diagnosis of male factor infertility. Compared with conventional IVF, use of ICSI was not associated with improved reproductive outcomes irrespective of male factor infertility diagnosis.
Corresponding Author: Sheree L. Boulet, DrPH, MPH, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS-K34, Atlanta, GA 30341 (email@example.com).
Author Contributions: Dr Boulet had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Boulet, Mehta, Kissin, Warner, Kawwass.
Drafting of the manuscript: Boulet, Mehta, Warner.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Boulet, Mehta, Warner.
Obtained funding: Mehta.
Administrative, technical, or material support: Mehta, Jamieson.
Study supervision: Kissin, Jamieson.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Funding/Support: This study was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award UL1TR000454 (Dr Mehta).
Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Disclaimer: The content, findings, and conclusions of this report are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the official position of the Centers for Disease Control and Prevention.